Neurotech Pharmaceuticals, Inc. is a privately-held biotechnology company focused on developing transformative therapies for chronic eye diseases. Our patented core technology platform, Encapsulated Cell Therapy (ECT), delivers a genetically-engineered ocular implanted device that continuously produces therapeutic proteins to the eye for multiple years. We have
implanted safely our device in several hundred patients.
Neurotech is clinically developing therapies for macular telangiectasia type 2 (MacTel) and glaucoma. Our treatment for MacTel has successfully completed a Phase 2 study and is nearing completion of enrolling two Phase 3 studies. For glaucoma we are taking a novel, neuro-protective approach in treating the disease. We are nearing completion of a 54-patient Phase 2
study conducted under an investigator-sponsored trial at Stanford University and Columbia University.